• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Rein Therapeutics Inc.

    5/6/26 1:29:55 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RNTX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Rein Therapeutics, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)




    00887A204

    (CUSIP Number)
    05/01/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    00887A204


    1Names of Reporting Persons

    LYTTON LAURENCE W
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    4,500,000.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    4,500,000.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,500,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.8 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  The percentage reported herein is calculated based on 78,039,032 shares of Common Stock outstanding following the completion of the Issuer's issuance and sale of 50,000,000 shares of Common Stock, as reported in the Rule 424(b)(5) Prospectus filed by the issuer on May 4, 2026.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Rein Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    12407 N. Mopac Expy., Suite 250, #390, Austin, Texas 78758
    Item 2. 
    (a)Name of person filing:

    Laurence W. Lytton
    (b)Address or principal business office or, if none, residence:

    467 Central Park West New York, NY 10025
    (c)Citizenship:

    USA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP Number(s):

    00887A204
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    4,500,000
    (b)Percent of class:

    5.8%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    4,500,000

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    4,500,000

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    LYTTON LAURENCE W
     
    Signature:/s/ Laurence W Lytton
    Name/Title:Reporting Person
    Date:05/06/2026
    Get the next $RNTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RNTX

    DatePrice TargetRatingAnalyst
    9/22/2025$10.00Buy
    H.C. Wainwright
    1/28/2025$8.00Buy
    Rodman & Renshaw
    More analyst ratings

    $RNTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Rein Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Rein Therapeutics with a rating of Buy and set a new price target of $10.00

    9/22/25 8:32:15 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Rein Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Rein Therapeutics with a rating of Buy and set a new price target of $8.00

    1/28/25 7:16:42 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Von Rickenbach Josef H bought $49,561 worth of Common stock (47,060 units at $1.05), increasing direct ownership by 305% to 62,514 units (SEC Form 4)

    4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

    5/28/26 8:15:59 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Windsor James Brian bought $25,000 worth of Common stock (25,000 units at $1.00), increasing direct ownership by 1,222% to 27,046 units (SEC Form 4)

    4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

    5/13/26 8:47:13 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Voss Capital, Lp bought $127,593 worth of shares (104,183 units at $1.22) (SEC Form 4)

    4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

    11/18/25 5:30:44 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNTX
    SEC Filings

    View All

    SEC Form PRE 14A filed by Rein Therapeutics Inc.

    PRE 14A - Rein Therapeutics, Inc. (0001420565) (Filer)

    5/28/26 4:43:15 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Rein Therapeutics Inc.

    10-Q - Rein Therapeutics, Inc. (0001420565) (Filer)

    5/15/26 7:56:40 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Rein Therapeutics Inc.

    SCHEDULE 13G - Rein Therapeutics, Inc. (0001420565) (Subject)

    5/6/26 1:29:55 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Von Rickenbach Josef H bought $49,561 worth of Common stock (47,060 units at $1.05), increasing direct ownership by 305% to 62,514 units (SEC Form 4)

    4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

    5/28/26 8:15:59 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Windsor James Brian bought $25,000 worth of Common stock (25,000 units at $1.00), increasing direct ownership by 1,222% to 27,046 units (SEC Form 4)

    4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

    5/13/26 8:47:13 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Voss Capital, Lp bought $127,593 worth of shares (104,183 units at $1.22) (SEC Form 4)

    4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

    11/18/25 5:30:44 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option

    Total gross proceeds increased to $57.5 millionOffering consisted solely of common stockProceeds expected to fund Phase 2 trial of LTI-03 in IPF through completion and support operations into 2028 AUSTIN, Texas, May 18, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ:RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today announced the closing of its previously announced underwritten public offering of common stock, including the full exercise of the underwriters' over-allotment option. The financing included new and existing healthcare-focused investors

    5/18/26 8:00:00 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock

    AUSTIN, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ:RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today announced the pricing of its underwritten public offering of fifty million shares of its common stock at a public offering price of $1.00 per share for aggregate gross proceeds of $50 million, prior to deducting underwriting discounts and commissions and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 7.5M shares of common stock at the public offering

    4/30/26 8:00:00 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis

    Patient enrollment accelerates across expanding number of clinical trial sites in multiple countries 8 patients enrolled, with additional patients expected in the near termEnrollment initiated in March 2026, with patients being added on a regular basisClinical trial sites active in the United States, Australia, and Poland, with additional countries expected to open in the near term AUSTIN, Texas, April 29, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today provided an update on its ongoing Phase 2

    4/29/26 8:00:00 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care